Enzyme PHLPP2 could be a viable drug target for treating prostate cancer

(Cold Spring Harbor Laboratory) Researchers propose a new druggable target that can put a damper on the spread of prostate cancer. Containing the threat at its origin organ greatly increases the survival rates of patients who suffer from the disease.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Authors: Yoshizawa T, Yamaguchi K, Kawata N, Ryuzaki H, Ogawa M, Obinata D, Mochida J, Takahashi S Abstract We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
The objective of this study was to identify favorable subgroups for alternative anti-androgen therapy among CRPC patients. Eighty-eight consecutive CRPC patients treated with alternative anti-androgen therapy were included in this study. All patients were treated with bicalutamide in the initial maximum androgen blockade (MAB) and switched to flutamide in the subsequent alternative anti-androgen therapy, combined with a luteinizing hormone-releasing hormone analogue. Several clinical and pathological factors for predicting the prostate-specific antigen (PSA) decline and PSA progression-free survival (PSA-PFS) of alternativ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Publication date: Available online 17 October 2019Source: Urology Case ReportsAuthor(s): Amer Amin, Alexandar Blazevski, Matthijs Scheltema, Phillip StrickerAbstractA 75-year-old man with a background history of total colectomy (including the distal rectum anal canal), has a suspicion of prostate cancer based on an elevated PSA and high risk features on multiparametric MRI. Here we describe the case in detail including the technique utilized to obtain prostate biopsy cores.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: Available online 17 October 2019Source: European UrologyAuthor(s): Wei Phin Tan, Thomas J. Polascik
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsThese results suggest that compared with PI-RADS v2, PI-RADS v2.1 could be preferable for evaluating TZ lesions.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Authors: De Luca S, Fiori C, Bollito E, Garrou D, Aimar R, Cattaneo G, De Cillis S, Manfredi M, Tota D, Massa F, Passera R, Porpiglia F Abstract BACKGROUND: To evaluate if multiparametric magnetic resonance (mpMRI)- transrectal ultrasound (TRUS) fusion targeted biopsy (TBx) versus untargeted standard biopsy (SBx) may decrease the rate of pathological upgrading of Gleason score (GS) 3+4 prostate cancer (PCa) at radical prostatectomy (RP). We also evaluated the impact of percent pattern 4 and cribriform glands at biopsy in the risk of GS 3 + 4 = 7 upgrading. METHODS: 301 patients with GS 3+4 PCa on biopsy (159 SB...
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
ConclusionThis survey was an informative trial to understand the verification status of patient-specific IMRT QA measurements for prostate cancer. In most institutions, the point dose measurement and dose distribution differences met the desired criteria.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Authors: Abrahamyan L, Huszti E, Bremner KE, Pechlivanoglou P, Mitsakakis N, Krahn M Abstract The epidemiology of prostate cancer (PC) continues to change. We evaluated the changes in incidence, in average age at diagnosis, and in survival from 1992 to 2015 in Ontario. We compared the cumulative incidence of PC-specific and non PC-specific mortality using two algorithms for cause of death: Method 1 assigned deaths from 'other cancers' to non PC-specific causes, and Method 2 assigned these cases to PC-specific mortality. There were 188,714 cases diagnosed with PC between 1992-2015 in Ontario. The average age at diag...
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
We present images of 177Lu-DOTATATE scan and 68Ga-DOTATATE PET/CT scan conducted on a 65-year-old man with prostate cancer with neuroendocrine differentiation, whose disease progressed despite conventional treatment and 177Lu-PSMA radioligand therapy; however, an extraordinary radiographic tumor remission, biochemical response, and improvement of clinical symptoms were observed after the patient underwent 177Lu-DOTATATE peptide receptor radionuclide therapy.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
A 63-year-old man, recently diagnosed with carcinoma of the prostate (Gleason’s score 4+4), with serum prostate-specific antigen 189.2 ng/mL, underwent 68Ga PSMA PET/CT scan for pretreatment staging. The study revealed abnormal tracer uptake in the prostatic bed region, the pelvic, abdominal, and mediastinal lymph nodes and diffuse metastases to the bilateral lungs. The lung metastasis was proved to be metastatic adenocarcinoma from analysis of bronchoalveolar lavage.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
More News: Cancer | Cancer & Oncology | Laboratory Medicine | Prostate Cancer